Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity.
J Pers Med
; 11(11)2021 Nov 12.
Article
en En
| MEDLINE
| ID: mdl-34834544
ABSTRACT
The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients-androgen deprivation therapy (ADT) alone-until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits-including significantly better overall survival (OS)-for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Guideline
Idioma:
En
Revista:
J Pers Med
Año:
2021
Tipo del documento:
Article
País de afiliación:
España